



WHAT IS CLAIMED IS:

1. A c-Kit kinase inhibitor comprising as an active ingredient, a compound represented by the general formula (I), a salt thereof or a hydrate of the foregoing:



(wherein  $R^1$  represents methyl, 2-methoxyethyl or a group represented by the formula (II):



10 (wherein  $R^{a3}$  represents methyl, cyclopropylmethyl or cyanomethyl;  $R^{a1}$  represents hydrogen, fluorine or hydroxyl; and  $R^{a2}$  represents 1-pyrrolydiny, 1-piperidinyl, 4-morpholinyl, dimethylamino or diethylamino);

15  $R^2$  represents cyano or  $-\text{CONHR}^{a4}$  (wherein  $R^{a4}$  represents hydrogen,  $\text{C}_{1-6}$  alkyl,  $\text{C}_{3-8}$  cycloalkyl,  $\text{C}_{1-6}$  alkoxy or  $\text{C}_{3-8}$  cycloalkoxy);

$R^3$  represents hydrogen, methyl, trifluoromethyl,

chlorine or fluorine; and

R<sup>4</sup> represents hydrogen, methyl, ethyl, n-propyl, cyclopropyl, 2-thiazolyl or 4-fluorophenyl).

2. The c-Kit kinase inhibitor according to claim  
5 1, wherein R<sup>1</sup> represents methyl.

3. The c-Kit kinase inhibitor according to claim 1, wherein R<sup>4</sup> represents methyl, ethyl or cyclopropyl.

4. The c-Kit kinase inhibitor according to claim 1, wherein R<sup>3</sup> represents hydrogen, chlorine or fluorine.

10 5. The c-Kit kinase inhibitor according to claim 1, wherein R<sup>2</sup> represents -CONHR<sup>a4</sup> (wherein R<sup>a4</sup> represents hydrogen or methoxy).

6. The c-Kit kinase inhibitor according to claim 1, wherein the compound represented by the general  
15 formula (I) is a compound selected from the group consisting of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide, 4-(3-chloro-4-(ethylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide, N6-methoxy-4-(3-chloro-4-  
20 (((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide and N6-methoxy-4-(3-chloro-4-(((ethylamino)carbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide.

25 7. An anticancer agent for treating a cancer expressing excessive c-Kit kinase or a mutant c-Kit

kinase, comprising as an active ingredient, the c-Kit kinase inhibitor according to claim 1.

5        8. The anticancer agent according to claim 7, wherein the cancer expressing excessive c-Kit kinase or a mutant c-Kit kinase is acute myelogenous leukemia, mast cell leukemia, a small cell lung cancer, GIST, a testicular cancer, an ovarian cancer, a breast cancer, a brain cancer, neuroblastoma or a colorectal cancer.

10       9. The anticancer agent according to claim 7, wherein the cancer expressing excessive c-Kit kinase or a mutant c-Kit kinase is acute myelogenous leukemia, a small cell lung cancer or GIST.

15       10. The anticancer agent according to claim 7, which is applied to a patient for which a cancer expressing excessive c-Kit kinase or a mutant c-Kit kinase is identified.

11. A therapeutic agent for mastocytosis, allergy or asthma, comprising as an active ingredient, the c-Kit kinase inhibitor according to claim 1.

20       12. A therapeutic method for a cancer, comprising administering to a patient suffering from a cancer expressing excessive c-Kit kinase or a mutant c-Kit kinase, a pharmacologically effective dose of the c-Kit kinase inhibitor according to claim 1.

25       13. The method according to claim 12, wherein the cancer expressing excessive c-Kit kinase or a mutant c-

Kit kinase is acute myelogenous leukemia, mast cell leukemia, a small cell lung cancer, GIST, a testicular cancer, an ovarian cancer, a breast cancer, a brain cancer, neuroblastoma or a colorectal cancer.

5           14. The method according to claim 12, wherein the cancer expressing excessive c-Kit kinase or a mutant c-Kit kinase is acute myelogenous leukemia, a small cell lung cancer or GIST.

10           15. A therapeutic method for a cancer, comprising the steps of:

extracting cancer cells from a patient suffering from a cancer;

confirming that the cancer cells are expressing excessive c-Kit kinase or a mutant c-Kit kinase; and

15           administering to the patient a pharmacologically effective dose of the c-Kit kinase inhibitor according to claim 1.

20           16. A therapeutic method for mastocytosis, allergy or asthma, comprising administering to a patient suffering from the disease, a pharmacologically effective dose of the c-Kit kinase inhibitor according to claim 1.

25           17. A method for inhibiting the c-Kit kinase activity, comprising applying to a cell expressing excessive c-Kit kinase or a mutant c-Kit kinase, a pharmacologically effective dose of the c-Kit kinase

inhibitor according to claim 1.